Metabolic side effects of new generation antipsychotics;Yeni kuşak antipsikotiklerin metabolik yan etkileri

Klinik Psikofarmakoloji Bulteni

Volumn 14, Issue 3, 2004, Pages 168-177

  Mete, Levent ^a   Ünsal, Pinar Çetinay ^a,b  

^a Izmir Ataturk Training and Research Hospital   (Turkey)

^b Psikiyatri Klinigi ^*  (Turkey)

Author keywords

Atypical antipsychotic; Diabetes mellitus; Lipid profile; Metabolic syndrome; Side effect; Weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; SERTINDOLE; ZIPRASIDONE;

COGNITION; DEPRESSION; DIABETES MELLITUS; HUMAN; METABOLIC DISORDER; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 4744351334     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology 1996; 124: 2-34
2. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579
3. Hansen BC. The metabolic syndrome X. Ann N Y Acad Sci 1999; 892: 1-24
4. Dynes JB. Diabetes in schizophrenia diabetes in non-psychotic medical patients. Dis Nerv Syst 1969; 30: 341-4
5. Mc Kee HA, D'arcy PF, Wilson PJK. Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 1986; 11: 297-299
6. Felker B, Yazel JJ, Short D. Mortality and medical co-morbidity among psychiatric patients: a review. Psychiatr 1996; 47: 1356-63
7. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73
8. Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, Kubo K, Momotani Y, Sanke T, Nanjo K. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 1987; 70 (suppl. 2): 90-93
9. Aliison DB, Mentore JL, Heo M, Chandler LP. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1695
10. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62 (suppl. 21): 7-10
11. Baptista T, Kin NM, Beaulieu S, Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205-219
12. Tandon R, Jibson MD. Safety and Tolerability: How do second generation atypical antipsychotics compare? Current Psychosis and Therapeutics Reports 2003; 1: 15-21
13. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine-induced weight gain. (letter) Ann Clin Psychiatry 1998; 10: 39
14. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62 (suppl. 23): 5-12
15. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year naturalistic study. Am J Psychiatry 2000; 157: 975-981
16. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: Weight related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100
17. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5: 437-440
18. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
19. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363
20. Ried LD, Renner BT, Bengtson MA, Wilcox BM, Acholonu WWJ. Weight change after an atypical antipsychotic switch. Ann Pharmacather 2003; 37: 1381-1386
21. Atmaca M, Kuloǧlu M, Tezcan E, Geçici Ö. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Sch Research 2003; 60: 99-100
22. Brecher M, Rak IW, Westhead EK. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287-292
23. Reinstein M, Sirotovskaya L, Jones L. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999; 18: 99-104
24. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes mellitus. Biol Psychiatry 1998; 44: 778-783
25. Daniel DG, Copeland LF. Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 2000; 9: 819-828
26. Meltzer HY. Long term efficacy of oral ziprasidone in schizophrenia: results of three controlled trials. International Congress on Schizophrenia Research; April 28-May 2 2001; Whistler, British Columbia, Canada
27. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153: 208-213
28. Silverstone T, Goodall E. Serotoninergic mechanisms in human feeding: Pharmacologic evidence. Appetite 1986; 7: 85-97
29. Fletcher PJ. Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacplogy (Berl) 1988; 96: 237-242
30. Bernstein JG. Psychotic drug induced weight gain: Mechanism and management. Clin Neuropharmacol 1988; 11: 194-206
31. Anil AE, Meltzer HY. Atipik antipsikotiklere baǧli glikoz metabolizmasi bozukluklari. Türk Psikiyatri Dergisi 2001; 12: 225-232
32. Auwerx J, Steals B. Leptin. Lancet 1998; 351: 737-742
33. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
34. Morimoto T, Yamamoto Y, Mobarakeh JI, Yanai K, Watanabe T, Watanabe T, Yamatodani A. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 1999; 67: 679-683
35. Dryden S, Brown M, King P, Williams G. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363-366
36. Liebowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851-864
37. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2c receptor gene. Nat Med 1998; 4: 1152-1156
38. Hagg S, Söderberg S, Ahren B, Olsson T, Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001; 62: 843-848
39. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546
40. Rockwell WJ, Ellinwood EH, Trader DW. Psychotropic drugs promoting weight gain: Health risks and treatment implications. South Med J 1983; 76: 1407-1412
41. Rietschel M, Naber D, Fimmers R, Propping P, Nothen MM. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2c receptor. Neuroreport 1997; 8: 1999-2003
42. Heisler LK, Chu HM, Tecott LH. Epilepsy and obesity in serotonin 5-HT2c receptor mutant mice. Ann N Y Acad Sci 1998; 861: 74-78
43. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1997; 18: 21-25
44. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on cytokines and soluble cytokine receptors. J Clin Psychopharmacol 1996; 16: 403-409
45. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000; 43: 164-166
46. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, Mc Camish MA, O'R Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl J Med 1999; 341: 879-884
47. Kivircik BB, Alptekin A, Çalişkan S, Çö mlekçi A, Örük G, Tümüklü M, Kürklü K, Arkar H, Türk A, Çalişkan M, Yeşil S, Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 795-799
48. Yamada J, Sugimoto Y, Ujikawa M. The serotonin precursor 5-hydroxytryptophon elevates serum leptin levels in mice. Eur J Pharmacol 1999; 383: 49-51
49. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozopine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108-111
50. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine (letter). Am J Psychiatry 1994; 151: 1395
51. Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report. J Clin Psychiatry 1983; 44: 347-348
52. Waldman JC, Yaren S. Atypical antipsychotics and glycemia: A case report. Can J Psychiatry 2002; 47: 686-687
53. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 45: 668-669
54. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999; 22: 1002-1003
55. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998; 59: 687-689
56. Isakov Isak, Klesmer J, Manhasset, Masand PS, Syracuse. Insulin-resistant hyperglycemia induced by clozapine. Psychosomatics 2000; 41: 373-374
57. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initation of quetiapine treatment (letter). J Clin Psychiatry 1999; 60: 556-557
58. Van Meter SA, Seaburg H, McLendon B, Doraiswamy PM. Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose. J Clin Psychiatry 2001; 62: 993-994
59. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalance of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294-299
60. Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 1381-1387
61. Plerides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997; 171: 90-91
62. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry 1996; 153: 737-738
63. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998; 74: 493-494
64. Kostakoǧlu AE, Yazici KM, Erbaş T, Güvener N. Ketoacidosis as a side-effect of clozapine: A case report. Acta Psychiatr Scand 1996; 93: 217-218
65. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994; 151: 1520-1521
66. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50: 148-149
67. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-443
68. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41: 369-370
69. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoocidosis Psychosomatics 2001; 42: 279-280
70. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865
71. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
72. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-345
73. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine- treated inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433
74. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 1996; 63: 269-274
75. Baudrie V, Chaouloff F. Repeated treatment with the 5-HT1a receptor agonist, ipsapirone, does not affect 8-OH-DPAT and stress-induced increases in plasma adrenaline levels in the rat. Eur J Pharmacol 1991; 198: 129-135
76. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991; 49: 101-109
77. Yazici KM, Erbaş T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106: 475-477
78. Meltzer HY. Clinical studies on the mechanism of action of clozapine. The dopamine serotonin hypothesis of schizophrenia. Psychopharmacology 1995; 99: 18-27
79. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wang DJ. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14: 87-96
80. Ahren B, Jarhult J, Lundquist I. Enhancement of insulin secretion during selective blockade of alpha-1 and alpha-2 adrenoreceptors in the rat: effects of somatostatin. Acta Physiol Scand 1982; 115: 257-260
81. Goldstein L, Henderson D. Atypical antipsychotic agents and diabetes mellitus. Primary Psychiatry 2000; 7: 65-68
82. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J, Caro JF. Acute and chronic effect of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996; 45: 699-701
83. Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T. Regulation of circulating leptin in humans. Endocrine 1997; 7: 1-8
84. Howes OD, Bhatnagar A, Goughran FP, Amiel SA. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161(2): 361-364
85. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic, drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry 1999; 29: 69-80
86. Seufert J, Kieffer TJ, Leech CA, Holz GG, Moritz W, Ricordi C, Habener JF. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-676
87. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80
88. Zimmet PZ. Challanges in diabetes epidemiology - from west to the rest. Diabetes Care 1992; 15: 232-252
89. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079-2081
90. Spivak B, Roitman S, Vered Y. Diminished suicidal and agressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998; 21: 245-250
91. Spivak B, Lamschtein C, Talmon Y. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98-101
92. Atmaca M, Kuloǧlu M, Tezcan E, Üstündaǧ B. Serum Leptin and Triglyceride Levels in Patients on Treaatment With Atypical Antipsychotics. J Clin Psychiatry 2003; 64: 598-604
93. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998; 115: 997-1001
94. Ernst ND, Obarzanek E, Clark MB, Briefel RR, Brown CD, Donato K. Cardiovascular health risks related to overweight. J Am Diet Assoc 1997; 97 (Suppl. 7):47-51
95. Işik D, Yildiz A, Kivircik B, Yücel G, Turgut K, Alptekin K, Tunca Z. Atipik Antipsikotik Iloçlarin Açlik Kan Şekeri, Kilo Artişi ve Beden/Kitle Indeksine Etkileri.39. Ulusal psikiyatri Kongresi Özet Kitabi, 2003: 367-368